Tutti gli studi
ReclutamentoConferma terapeutica (Fase III)Interventistico

A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months

This study is for people aged 12 and older with severe haemophilia A who have already received treatment. It's testing a new medicine called efanesoctocog alfa (pronounced: eh-fan-eh-sock-toh-kog AL-fa), which is given into a vein. The main goal is to find out if this medicine helps people become more physically active and improves their joint health over a period of 24 months. Researchers will measure physical activity using questionnaires and wearable trackers, and they'll check joint health with special scans and by looking at how joints are feeling. They will also keep an eye on safety, such as any side effects, and how many bleeds participants experience. This is a vital next step to understand how this new treatment might help people with haemophilia A live fuller, more active lives.

A colpo d'occhio

Stato
Reclutamento
Fase
Conferma terapeutica (Fase III)
Sponsor
Swedish Orphan Biovitrum AB (publ)
Obiettivo di iscrizione
81
Inizio
28 Feb 2023

Di cosa tratta questo studio?

Imagine a new type of treatment that could help people with severe haemophilia A live more active lives and protect their joints. That's what this important study is all about. Haemophilia A is a condition where your blood doesn't clot properly, leading to bleeding, especially into joints, which can cause pain and long-term damage. This study is testing a promising new medicine called efanesoctocog alfa, which is given into a vein.

The main aim of the study is to see how this new medicine affects how much physical activity people can do and how healthy their joints become over a 24-month period. Researchers will be using special questionnaires and wearable tracking devices to measure activity levels. They will also use imaging scans, like MRI, to get a detailed look at joint health. They'll be carefully watching for any bleeds, pain, or injuries, and how these might impact daily life, like going to school or work.

Ultimately, this study hopes to show how effective efanesoctocog alfa is in reducing bleeding episodes and improving the quality of life for people with severe haemophilia A. It's a crucial step in understanding if this treatment can help people manage their condition better and enjoy a more active lifestyle with healthier joints.

Punti chiave

  • This study is testing a new haemophilia A treatment called efanesoctocog alfa.
  • It aims to see if the medicine improves physical activity and joint health.
  • Participants will be aged 12 and over with severe haemophilia A.
  • The study lasts 24 months and involves regular checks and activity monitoring.
  • It's a Phase 3 study, meaning it's a key stage before potential wider use.

Chi può essere idoneo?

To join this study, people must be at least 12 years old and have severe haemophilia A. They should have already received other treatments for their condition in the past.

This study is open to both males and females. The doctors will also check other health details to make sure the study is a good fit and safe for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you 12 years old or older?
  2. Do you have severe haemophilia A?
  3. Have you been treated for haemophilia A before?
  4. Are you able to attend regular clinic visits for two years?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you join this study, you'll receive the study medicine, efanesoctocog alfa, which is given into a vein. You will have regular visits to the clinic over a period of 24 months. During these visits, the study team will carry out health checks, take blood samples, and ask you about your symptoms and how you're feeling. You'll also complete questionnaires about your physical activity and wear a tracker to measure how active you are. Joint health will be monitored through examinations and imaging scans, like MRI. There will also be a follow-up period after the treatment ends to ensure your safety.

Rischi e benefici potenziali

Taking part in any study has potential benefits and risks. You might benefit from receiving a new treatment that could improve your bleeds, joint health, and physical activity. However, there's always a chance of side effects from the medication or that it might not work for you. The study team will carefully monitor your health throughout. Remember, participating is entirely your choice, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (14)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Croazia
  • —
    Non verificato
    Norvegia
  • —
    Non verificato
    Italia
  • —
    Non verificato
    Repubblica Ceca
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Svezia
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Austria
  • —
    Non verificato
    Belgio
  • —
    Non verificato
    Grecia
  • —
    Non verificato
    Slovenia
  • —
    Non verificato
    Irlanda

Domande comuni

What is haemophilia A?

Haemophilia A is a condition where your blood doesn't clot properly because you are missing an important protein. This can lead to bleeding inside the body, especially into joints.

What is efanesoctocog alfa?

Efanesoctocog alfa is the name of the new medicine being tested in this study. It's given into a vein to help with blood clotting in people with haemophilia A.

Quanto durerà lo studio?

The main treatment part of the study will last for 24 months (two years), with some follow-up after that.

Will I know if I'm getting the active medicine?

Yes, in this particular study, called an 'open-label' study, all participants will receive the study medicine, efanesoctocog alfa.

My child is 12, can they join?

Yes, the study is for people aged 12 years and older, but a doctor will need to check if it's suitable for your child based on other health details.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A phase 3b open-label, multicenter study evaluating physical…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.